Bax-interacting factor-1 expression in prostate cancer

Domenico Coppola, Cecilia Oliveri, Zena Sayegh, David Boulware, Yoshinori Takahashi, Julio Pow-Sang, Julie Y. Djeu, Hong Gang Wang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Bax-interacting factor (Bif)-1 protein is a member of the endophilin B family that binds to and activates the proapoptotic Bax protein in response to apoptotic signals. Loss of Bif-1 suppresses the intrinsic pathway of apoptosis and promotes tumorigenesis. We examined the expression levels of Bif-1 protein in human prostate cancer. Materials and Methods: Thirty-nine archival tissue specimens of human prostate cancer, and a human prostate cancer tissue microarray containing 19 samples of normal prostate, 26 samples of benign prostatic hyperplasias (BPHs), 30 samples of high-grade prostatic intraepithelial neoplasia (PIN), and 153 samples of prostate cancer, were selected for immunohistochemical staining with Bif-1 antibody. The slides were scored by 2 independent observers. Results: Nontissue microarray samples: moderate to strong Bif-1 staining was identified in 38 of 39 prostate cancer samples. In 32 cases, foci of PIN were identified adjacent to prostate cancer samples. Of these, 29 samples (90.6%) showed strong and diffuse Bif-1 staining. Benign prostatic hyperplasias, identified in 27 cases, was weakly Bif-1 positive in 88.9% of cases. Tissue microarray samples: 38.6% (59 of 153) of prostate cancer samples showed moderate to strong Bif-1 expression, and 21.6% (33 of 153) were Bif-1 negative. Bif-1 expression was moderate to strong in 76.7% (23 of 30) of PIN. Bif-1 was weak to moderate in 53.8% (14 of 26) of BPH and negative in 46.2% (12 of 26) of them. Low to moderate Bif-1 was seen in 89.5% of normal prostate samples. Conclusion: The loss of Bif-1 expression in a subset of prostate cancer samples is in agreement with the proapoptotic function of Bif-1. The significance of the increased Bif-1 in a subgroup of prostate cancer samples and in PIN remains to be determined. It seems that Bif-1 has a role in prostate cancer, providing the rationale for using Bif-1 as a target for prostate anticancer therapy.

Original languageEnglish (US)
Pages (from-to)117-121
Number of pages5
JournalClinical Genitourinary Cancer
Volume6
Issue number2
DOIs
StatePublished - Jan 1 2008

Fingerprint

Prostatic Neoplasms
Prostatic Intraepithelial Neoplasia
Prostatic Hyperplasia
Prostate
Staining and Labeling
bcl-2-Associated X Protein
Carcinogenesis
Apoptosis
Antibodies
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Coppola, Domenico ; Oliveri, Cecilia ; Sayegh, Zena ; Boulware, David ; Takahashi, Yoshinori ; Pow-Sang, Julio ; Djeu, Julie Y. ; Wang, Hong Gang. / Bax-interacting factor-1 expression in prostate cancer. In: Clinical Genitourinary Cancer. 2008 ; Vol. 6, No. 2. pp. 117-121.
@article{d82dd4720ff74d22a7abb39d99b5c046,
title = "Bax-interacting factor-1 expression in prostate cancer",
abstract = "Background: Bax-interacting factor (Bif)-1 protein is a member of the endophilin B family that binds to and activates the proapoptotic Bax protein in response to apoptotic signals. Loss of Bif-1 suppresses the intrinsic pathway of apoptosis and promotes tumorigenesis. We examined the expression levels of Bif-1 protein in human prostate cancer. Materials and Methods: Thirty-nine archival tissue specimens of human prostate cancer, and a human prostate cancer tissue microarray containing 19 samples of normal prostate, 26 samples of benign prostatic hyperplasias (BPHs), 30 samples of high-grade prostatic intraepithelial neoplasia (PIN), and 153 samples of prostate cancer, were selected for immunohistochemical staining with Bif-1 antibody. The slides were scored by 2 independent observers. Results: Nontissue microarray samples: moderate to strong Bif-1 staining was identified in 38 of 39 prostate cancer samples. In 32 cases, foci of PIN were identified adjacent to prostate cancer samples. Of these, 29 samples (90.6{\%}) showed strong and diffuse Bif-1 staining. Benign prostatic hyperplasias, identified in 27 cases, was weakly Bif-1 positive in 88.9{\%} of cases. Tissue microarray samples: 38.6{\%} (59 of 153) of prostate cancer samples showed moderate to strong Bif-1 expression, and 21.6{\%} (33 of 153) were Bif-1 negative. Bif-1 expression was moderate to strong in 76.7{\%} (23 of 30) of PIN. Bif-1 was weak to moderate in 53.8{\%} (14 of 26) of BPH and negative in 46.2{\%} (12 of 26) of them. Low to moderate Bif-1 was seen in 89.5{\%} of normal prostate samples. Conclusion: The loss of Bif-1 expression in a subset of prostate cancer samples is in agreement with the proapoptotic function of Bif-1. The significance of the increased Bif-1 in a subgroup of prostate cancer samples and in PIN remains to be determined. It seems that Bif-1 has a role in prostate cancer, providing the rationale for using Bif-1 as a target for prostate anticancer therapy.",
author = "Domenico Coppola and Cecilia Oliveri and Zena Sayegh and David Boulware and Yoshinori Takahashi and Julio Pow-Sang and Djeu, {Julie Y.} and Wang, {Hong Gang}",
year = "2008",
month = "1",
day = "1",
doi = "10.3816/CGC.2008.n.018",
language = "English (US)",
volume = "6",
pages = "117--121",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

Coppola, D, Oliveri, C, Sayegh, Z, Boulware, D, Takahashi, Y, Pow-Sang, J, Djeu, JY & Wang, HG 2008, 'Bax-interacting factor-1 expression in prostate cancer', Clinical Genitourinary Cancer, vol. 6, no. 2, pp. 117-121. https://doi.org/10.3816/CGC.2008.n.018

Bax-interacting factor-1 expression in prostate cancer. / Coppola, Domenico; Oliveri, Cecilia; Sayegh, Zena; Boulware, David; Takahashi, Yoshinori; Pow-Sang, Julio; Djeu, Julie Y.; Wang, Hong Gang.

In: Clinical Genitourinary Cancer, Vol. 6, No. 2, 01.01.2008, p. 117-121.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bax-interacting factor-1 expression in prostate cancer

AU - Coppola, Domenico

AU - Oliveri, Cecilia

AU - Sayegh, Zena

AU - Boulware, David

AU - Takahashi, Yoshinori

AU - Pow-Sang, Julio

AU - Djeu, Julie Y.

AU - Wang, Hong Gang

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Bax-interacting factor (Bif)-1 protein is a member of the endophilin B family that binds to and activates the proapoptotic Bax protein in response to apoptotic signals. Loss of Bif-1 suppresses the intrinsic pathway of apoptosis and promotes tumorigenesis. We examined the expression levels of Bif-1 protein in human prostate cancer. Materials and Methods: Thirty-nine archival tissue specimens of human prostate cancer, and a human prostate cancer tissue microarray containing 19 samples of normal prostate, 26 samples of benign prostatic hyperplasias (BPHs), 30 samples of high-grade prostatic intraepithelial neoplasia (PIN), and 153 samples of prostate cancer, were selected for immunohistochemical staining with Bif-1 antibody. The slides were scored by 2 independent observers. Results: Nontissue microarray samples: moderate to strong Bif-1 staining was identified in 38 of 39 prostate cancer samples. In 32 cases, foci of PIN were identified adjacent to prostate cancer samples. Of these, 29 samples (90.6%) showed strong and diffuse Bif-1 staining. Benign prostatic hyperplasias, identified in 27 cases, was weakly Bif-1 positive in 88.9% of cases. Tissue microarray samples: 38.6% (59 of 153) of prostate cancer samples showed moderate to strong Bif-1 expression, and 21.6% (33 of 153) were Bif-1 negative. Bif-1 expression was moderate to strong in 76.7% (23 of 30) of PIN. Bif-1 was weak to moderate in 53.8% (14 of 26) of BPH and negative in 46.2% (12 of 26) of them. Low to moderate Bif-1 was seen in 89.5% of normal prostate samples. Conclusion: The loss of Bif-1 expression in a subset of prostate cancer samples is in agreement with the proapoptotic function of Bif-1. The significance of the increased Bif-1 in a subgroup of prostate cancer samples and in PIN remains to be determined. It seems that Bif-1 has a role in prostate cancer, providing the rationale for using Bif-1 as a target for prostate anticancer therapy.

AB - Background: Bax-interacting factor (Bif)-1 protein is a member of the endophilin B family that binds to and activates the proapoptotic Bax protein in response to apoptotic signals. Loss of Bif-1 suppresses the intrinsic pathway of apoptosis and promotes tumorigenesis. We examined the expression levels of Bif-1 protein in human prostate cancer. Materials and Methods: Thirty-nine archival tissue specimens of human prostate cancer, and a human prostate cancer tissue microarray containing 19 samples of normal prostate, 26 samples of benign prostatic hyperplasias (BPHs), 30 samples of high-grade prostatic intraepithelial neoplasia (PIN), and 153 samples of prostate cancer, were selected for immunohistochemical staining with Bif-1 antibody. The slides were scored by 2 independent observers. Results: Nontissue microarray samples: moderate to strong Bif-1 staining was identified in 38 of 39 prostate cancer samples. In 32 cases, foci of PIN were identified adjacent to prostate cancer samples. Of these, 29 samples (90.6%) showed strong and diffuse Bif-1 staining. Benign prostatic hyperplasias, identified in 27 cases, was weakly Bif-1 positive in 88.9% of cases. Tissue microarray samples: 38.6% (59 of 153) of prostate cancer samples showed moderate to strong Bif-1 expression, and 21.6% (33 of 153) were Bif-1 negative. Bif-1 expression was moderate to strong in 76.7% (23 of 30) of PIN. Bif-1 was weak to moderate in 53.8% (14 of 26) of BPH and negative in 46.2% (12 of 26) of them. Low to moderate Bif-1 was seen in 89.5% of normal prostate samples. Conclusion: The loss of Bif-1 expression in a subset of prostate cancer samples is in agreement with the proapoptotic function of Bif-1. The significance of the increased Bif-1 in a subgroup of prostate cancer samples and in PIN remains to be determined. It seems that Bif-1 has a role in prostate cancer, providing the rationale for using Bif-1 as a target for prostate anticancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=58149190801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149190801&partnerID=8YFLogxK

U2 - 10.3816/CGC.2008.n.018

DO - 10.3816/CGC.2008.n.018

M3 - Article

C2 - 18824435

AN - SCOPUS:58149190801

VL - 6

SP - 117

EP - 121

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 2

ER -

Coppola D, Oliveri C, Sayegh Z, Boulware D, Takahashi Y, Pow-Sang J et al. Bax-interacting factor-1 expression in prostate cancer. Clinical Genitourinary Cancer. 2008 Jan 1;6(2):117-121. https://doi.org/10.3816/CGC.2008.n.018